. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Pharm Res. 2013 Feb 16;30(4):932–950. doi: 10.1007/s11095-012-0912-4

Table VI.

CYP Phenotyping of IND24 and IND81 at 1 μM in Human Liver Microsomes

Enzyme	Treatment	IND24				IND81
		Measured Conc. (μM)	Disappearance		CYP?	Measured Conc. (μM)	Disappearance		CYP?
		Measured Conc. (μM)	%	% Δ^a	CYP?	Measured Conc. (μM)	%	% Δ^a	CYP?
Irreversible incubation condition
Negative Control	No NADPH/No Inhibitor	0.622				0.899	0
Maximum Metabolism	NADPH/No Inhibitor	0.733	0 (−18)	0		0.143	84	0
CYP1A2	NADPH + Furafylline	0.766	0 (−23)	0	Unlikely	0.534	41	43	Unlikely
Reversible incubation condition
Negative Control	No NADPH/No Inhibitor	0.654	0			0.664	0
Maximum Metabolism	NADPH/No Inhibitor	0.655	0	0		0.226	66	0
CYP2C9	NADPH + Sulphaphenazol	0.566	14	0 (−14)	Unlikely	0.238	64	1.8	Unlikely
CYP2C19	NADPH + N-3-B	0.537	18	0 (−18)	Unlikely	0.283	57	8.5	Possible
CYP2D6	NADPH + Quinidine	0.555	15	0 (−15)	Unlikely	0.300	55	11	Likely
CYP3A4	NADPH + Ketoconazole	0.557	15	0 (−15)	Unlikely	0.324	51	15	Likely

The involvement of the CYP considered unlikely for values <5; possible for values 5–10; and likely for values >10